Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

GLP-1 antidiabetic drugs, which reduce body mass by 25%, impact the processed food or alcohol industry and force fashion and insurance to transform. The unwanted side effect in medicine is any ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.